INmune Bio
INMB
79 hedge funds and large institutions have $12.7M invested in INmune Bio in 2025 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 15 reducing their positions, and 22 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 15
2.41% less ownership
Funds ownership: 26.89% → 24.48% (-2.4%)
4% less funds holding
Funds holding: 82 → 79 (-3)
14% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 22
60% less call options, than puts
Call options by funds: $4.21M | Put options by funds: $10.5M
74% less capital invested
Capital invested by funds: $48.1M → $12.7M (-$35.4M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.29M |
| 2 |
BlackRock
New York
|
+$1.64M |
| 3 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$865K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$653K |
| 5 |
JP Morgan Chase
New York
|
+$489K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PP
Praetorian PR
Rincon,
Puerto Rico
|
-$6.35M |
| 2 |
GC
GatePass Capital
Independence,
Ohio
|
-$1.84M |
| 3 |
Millennium Management
New York
|
-$1.46M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$745K |
| 5 |
PHS
Pekin Hardy Strauss
Chicago,
Illinois
|
-$736K |
INMB Hedge Fund Activity: Q2 2025 in Review
79 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q2 2025, worth a combined $12.7M — down 74% from $48.1M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of INMB and 19 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 29 added.
The largest buyer was UBS Group, adding an estimated $2.29M. The largest seller was Praetorian PR, exiting entirely with an estimated $6.35M sold.
- 79 institutional investors held INmune Bio (INMB) as of Q2 2025, down from 82 in Q1 2025.
- Funds reported $12.7M of INmune Bio stock for Q2 2025, down 74% quarter-over-quarter.
- 19 funds opened new INmune Bio positions in Q2 2025 and 22 closed out, a net change of -3 holders.
- The largest INmune Bio buyer in Q2 2025 was UBS Group, an estimated $2.29M added.
- The largest INmune Bio seller in Q2 2025 was Praetorian PR, an estimated $6.35M sold.
Based on aggregated 13F filings for Q2 2025.